Barclays PLC Sells 133,676 Shares of IQVIA Holdings Inc. $IQV

Key Points

• Barclays PLC sold 133,676 IQVIA shares in the third quarter, cutting its holding by 30.8% to 300,730 shares (about 0.18% of the company) worth roughly $57.12 million.
• IQVIA beat quarterly expectations (EPS $3.42 vs $3.40; revenue $4.36B, +10.3% YoY) and retains a consensus Buy rating with an average price target of $229.13, well above the recent ~$178.87 share price.

Barclays PLC reduced its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 30.8% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 300,730 shares of the medical research company's stock after selling 133,676 shares during the quarter. Barclays PLC owned approximately 0.18% of IQVIA worth $57,121,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in the business. Versant Capital Management Inc raised its holdings in IQVIA by 6.3% during the third quarter. Versant Capital Management Inc now owns 899 shares of the medical research company's stock worth $171,000 after acquiring an additional 53 shares in the last quarter. CVA Family Office LLC raised its holdings in shares of IQVIA by 11.6% in the 3rd quarter. CVA Family Office LLC now owns 654 shares of the medical research company's stock valued at $124,000 after purchasing an additional 68 shares during the period. Huntington National Bank lifted its stake in IQVIA by 7.8% in the 3rd quarter. Huntington National Bank now owns 969 shares of the medical research company's stock valued at $184,000 after purchasing an additional 70 shares during the last quarter. UMB Bank n.a. lifted its stake in IQVIA by 11.0% in the 3rd quarter. UMB Bank n.a. now owns 749 shares of the medical research company's stock valued at $142,000 after purchasing an additional 74 shares during the last quarter. Finally, E Fund Management Co. Ltd. increased its position in IQVIA by 3.7% during the second quarter. E Fund Management Co. Ltd. now owns 2,099 shares of the medical research company's stock worth $331,000 after buying an additional 74 shares during the last quarter. Institutional investors and hedge funds own 89.62% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the company. JPMorgan Chase & Co. cut their price objective on IQVIA from $255.00 to $225.00 and set an "overweight" rating for the company in a research report on Friday, February 6th. BMO Capital Markets set a $250.00 price objective on shares of IQVIA in a research report on Friday, February 6th. Royal Bank Of Canada started coverage on shares of IQVIA in a research report on Tuesday, March 3rd. They issued an "outperform" rating and a $221.00 price objective on the stock. Jefferies Financial Group cut their target price on shares of IQVIA from $270.00 to $255.00 and set a "buy" rating for the company in a research note on Friday, February 6th. Finally, Weiss Ratings reaffirmed a "hold (c)" rating on shares of IQVIA in a research report on Thursday, January 22nd. Two research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of $229.13.

IQVIA Stock Performance

Shares of NYSE:IQV opened at $178.87 on Tuesday. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 2.09. IQVIA Holdings Inc. has a 12-month low of $134.65 and a 12-month high of $247.04. The company's 50 day moving average price is $206.26 and its two-hundred day moving average price is $207.53. The firm has a market cap of $30.35 billion, a PE ratio of 22.76, a PEG ratio of 1.68 and a beta of 1.40.

IQVIA (NYSE:IQV - Get Free Report) last issued its quarterly earnings results on Thursday, February 5th. The medical research company reported $3.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.40 by $0.02. IQVIA had a return on equity of 30.50% and a net margin of 8.34%.The business had revenue of $4.36 billion during the quarter, compared to analysts' expectations of $4.24 billion. During the same period in the previous year, the company posted $3.12 earnings per share. The firm's revenue for the quarter was up 10.3% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. Equities research analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

IQVIA Profile

IQVIA NYSE: IQV is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA's principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.